Astrazeneca (AZN) Total Debt (2006 - 2026)
Astrazeneca (AZN) total debt from Mar 31, 2006 to Mar 31, 2026. The current Astrazeneca (AZN) total debt is $67B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Debt
Total Debt
Astrazeneca (AZN) Total Debt CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +4.25% |
| 3 Years TTM | +3.76% |
| 5 Years TTM | +6.21% |
| 10 Years TTM | +5.11% |
| All Time TTM | +8.50% |
Annual Total Debt change of Astrazeneca (AZN)
| Year | Total Debt | Change |
|---|---|---|
| 2025 | $65B | +3.47% |
| 2024 | $63B | +1.95% |
| 2023 | $62B | +4.25% |
| 2022 | $59B | -10.07% |
| 2021 | $66B | +29.33% |
| 2020 | $51B | +9.21% |
| 2019 | $47B | +0.37% |
| 2018 | $47B | -0.22% |
| 2017 | $47B | +1.86% |
| 2016 | $46B | +10.19% |
| 2015 | $42B | +6.84% |
| 2014 | $39B | +19.31% |
| 2013 | $33B | +10.36% |
| 2012 | $30B | +0.76% |
| 2011 | $29B | -10.27% |
| 2010 | $33B | -4.05% |
| 2009 | $34B | +10.39% |
| 2008 | $31B | -6.51% |
| 2007 | $33B | +127.62% |
| 2006 | $15B | N/A |
Comparison Astrazeneca (AZN) total debt with competitors
Astrazeneca (AZN) total debt is $66.63B.
| Ticker | Name | Total Debt | Upside |
|---|---|---|---|
| MIRA | Mira Pharmaceuticals Inc | $114761.00 | -100.00% |
| NSRX | Nasus Pharma Ltd | $2.24M | -100.00% |
| MDCX | MDCorp | $6.00M | -99.99% |
| MDCXW | Medicus Pharma Ltd warrant | $6.00M | -99.99% |
| AMRN | Amarin Corp | $196.35M | -99.71% |
| SCLX | Scilex Holding Company | $547.71M | -99.18% |
| BIIB | Biogen Inc | $10.83B | -83.74% |
| OGN | Organon & Company | $12.09B | -81.85% |
| GRFS | Grifols SA | $12.24B | -81.62% |
| SNY | Sanofi | $54.88B | -17.63% |
| GSK | GSK Plc | $59.93B | -10.06% |
| BMY | Bristol-Myers Squibb Company | $66.37B | -0.39% |
| NVS | Novartis AG | $79.61B | +19.47% |
| PFE | Pfizer Inc | $117.21B | +75.92% |
| JNJ | Johnson & Johnson | $119.71B | +79.66% |
| NVO | Novo Nordisk | $356.16B | +434.52% |